An AAV-ie based Vaccine effectively protects against SARS-CoV-2 and Circulating Variants
Zhao, S.; Tan, F.; Ke, J.; Yang, J.; Lin, C.-b.; Wang, H.; zhong, g.
Show abstract
Prophylactic vaccines against SARS-CoV-2 have been extensively developed globally to overcome the COVID-19 pandemic. However, recently emerging SARS-CoV-2 variants B.1.1.7 and B.1.351 limit the vaccine protection effects and successfully escape antibody cocktail treatment. Herein, based on our previously engineered adeno-associated viral (AAV) vector, AAV-ie, and systematic immunogen screening, we developed an AAV-ie-S1 vaccine with thermostability, high efficiency, safety, and single-dose vaccination advantage. Importantly, the AAV-ie-S1 immune sera efficiently neutralize B.1.1.7 and B.1.351, indicating a potential to circumvent the spreading of SARS-CoV-2.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 93%
- Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial 92%
- A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus 92%
Similar papers in this journal
Similar papers in this journal
- Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins 94%
- Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination 94%
- Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease 94%
Similar papers in this journal
Similar papers in this journal
- Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates 95%
- Preclinical establishment of a divalent vaccine against SARS-CoV-2 94%
- A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.